Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.

Hdl Handle:
http://hdl.handle.net/10147/127244
Title:
Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.
Authors:
Greene, Catherine M; McElvaney, Noel G
Affiliation:
Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland. cmgreene@rcsi.ie
Citation:
Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. 2009, 158 (4):1048-58 Br. J. Pharmacol.
Journal:
British journal of pharmacology
Issue Date:
Oct-2009
URI:
http://hdl.handle.net/10147/127244
DOI:
10.1111/j.1476-5381.2009.00448.x
PubMed ID:
19845686
Additional Links:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785526/pdf/bph0158-1048.pdf
Abstract:
Chronic inflammatory lung diseases such as cystic fibrosis and emphysema are characterized by higher-than-normal levels of pulmonary proteases. While these enzymes play important roles such as bacterial killing, their dysregulated expression or activity can adversely impact on the inflammatory process. The existence of efficient endogenous control mechanisms that can dampen or halt this overexuberant protease activity in vivo is essential for the effective resolution of inflammatory lung disease. The function of pulmonary antiproteases is to fulfil this role. Interestingly, in addition to their antiprotease activity, protease inhibitors in the lung also often possess other intrinsic properties that contribute to microbial killing or termination of the inflammatory process. This review will outline important features of chronic inflammation that are regulated by pulmonary proteases and will describe the various mechanisms by which antiproteases attempt to counterbalance exaggerated protease-mediated inflammatory events. These proteases, antiproteases and their modifiers represent interesting targets for therapeutic intervention.
Item Type:
Article
Language:
en
MeSH:
Animals; Chronic Disease; Drug Discovery; Humans; Lung Diseases; Peptide Hydrolases; Protease Inhibitors
ISSN:
1476-5381

Full metadata record

DC FieldValue Language
dc.contributor.authorGreene, Catherine Men
dc.contributor.authorMcElvaney, Noel Gen
dc.date.accessioned2011-04-05T15:09:31Z-
dc.date.available2011-04-05T15:09:31Z-
dc.date.issued2009-10-
dc.identifier.citationProteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. 2009, 158 (4):1048-58 Br. J. Pharmacol.en
dc.identifier.issn1476-5381-
dc.identifier.pmid19845686-
dc.identifier.doi10.1111/j.1476-5381.2009.00448.x-
dc.identifier.urihttp://hdl.handle.net/10147/127244-
dc.description.abstractChronic inflammatory lung diseases such as cystic fibrosis and emphysema are characterized by higher-than-normal levels of pulmonary proteases. While these enzymes play important roles such as bacterial killing, their dysregulated expression or activity can adversely impact on the inflammatory process. The existence of efficient endogenous control mechanisms that can dampen or halt this overexuberant protease activity in vivo is essential for the effective resolution of inflammatory lung disease. The function of pulmonary antiproteases is to fulfil this role. Interestingly, in addition to their antiprotease activity, protease inhibitors in the lung also often possess other intrinsic properties that contribute to microbial killing or termination of the inflammatory process. This review will outline important features of chronic inflammation that are regulated by pulmonary proteases and will describe the various mechanisms by which antiproteases attempt to counterbalance exaggerated protease-mediated inflammatory events. These proteases, antiproteases and their modifiers represent interesting targets for therapeutic intervention.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785526/pdf/bph0158-1048.pdfen
dc.subject.meshAnimals-
dc.subject.meshChronic Disease-
dc.subject.meshDrug Discovery-
dc.subject.meshHumans-
dc.subject.meshLung Diseases-
dc.subject.meshPeptide Hydrolases-
dc.subject.meshProtease Inhibitors-
dc.titleProteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.en
dc.typeArticleen
dc.contributor.departmentRespiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland. cmgreene@rcsi.ieen
dc.identifier.journalBritish journal of pharmacologyen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.